DM Intelligence Picked up ¥10M in Angel Round of Financing

作者: Mailman 2021-05-06 09:41
智睿医药
http://www.dm-intelligencepharm.com/
企业数据由 动脉橙 提供支持
基于人工智能的新药研发商 | 天使轮 | 运营中
中国-广东
2021-04-21
融资金额:近千万人民币
广州南山创投
查看

(VCBeat) Apr. 25, 2021 -- On April 19, 2021, Guangzhou-based DM Intelligence, a new drug R&D company, announced that it had secured nearly ten million yuan in the angel funding round, led by Guangzhou Nanshan Venture Capital. Financial terms of the transaction were not disclosed. The funds are earmarked for the construction of DM Intelligence's core platform (the AI-powered new drug discovery platform) and the pre-clinical development of its AI-driven new drugs.


Based on a large number of diversified databases, with a variety of optimized machine learning and deep learning algorithms combined with intelligent CADD as the core, aiming at new drug HIT, LEAD discovery, PCC optimization as the goal, and supercomputer as the accelerator, DM Intelligence has established an AI-based platform for drug discovery based on drug activity and ADMET property prediction, drug-target interaction and small molecule generation, with advantages in the speed, precision and breadth of innovative drug discovery.


Dr. Xie Weidong, the chairman and general manager of DM Intelligence, said, "Combined with AI technology, the company has started the fast forward mode of AI-based new drug R&D, established a comprehensive algorithm model from multiple dimensions, and greatly improved the screening efficiency. DM Intelligence has discovered novel and diversified active compounds with global patents. Currently, the company focuses on the pipeline of proven and urgently needed small-molecule drugs for targeted therapies of cancer, neurodegeneration, infection and autoimmunity. The company's AI-based drug discovery platform shows amazing potential.


"After more than two years of development, DM Intelligence has developed more than 10 internal pipelines, 5 pipelines with external cooperation. The pipeline for Parkinson's disease is progressing rapidly and has shown excellent results compared with similar drugs in development. Next, DM Intelligence will focus on the relevant pipelines to further promote the development of the enterprise. The AI platform of DM Intelligence integrates multiple disciplines such as pharmaceutical chemistry, biology, mathematics, and bioinformatics to establish a comprehensive algorithm model from multiple dimensions. The screening efficiency is much higher than traditional methods, and many compounds developed by the platform have been granted global patent protection," said Xie Weidong.


>>>>

About Guangzhou Nanshan Venture Capital


Guangzhou Nanshan Venture Capital is a fund for scientific and technological achievement transformation, led by Zhong Nanshan, academician of Chinese Academy of Engineering, under the management of Guangdong Nanshan Medical Innovation Research Institute. The fund mainly invests in research institutions in biomedical and related fields, new R&D companies, and transformation projects of scientific and technological achievements in universities and colleges.

相关赛道 研发制造外包
注:文中如果涉及企业数据,均由受访者向分析师提供并确认。
声明:动脉网所刊载内容之知识产权为动脉网及相关权利人专属所有或持有。转载请联系tg@vcbeat.net。

Mailman

医疗行业观察者

分享
动脉橙
以上数据来自动脉橙产业智库

我们以独创的在线数据库方式,为健康产业人士提供全方位和实时的市场资讯、行业数据和分析师见解。现已覆盖数字健康、医疗器械、生物医药等近100+细分领域,涉及公司名单、招投标、投融资信息、头部企业动态等各类数据并持续更新。

点击 【申请试用】了解动脉橙产业智库更多内容。
精彩内容推荐

【首发】百迈生物医药本年度已完成超亿元融资

Qiyu Bio Lands Tens of Millions of Yuan in Series A Financing

智能芯片药丸公司Proteus Digital Health再获5000万美元融资

【首发】生命科学全流程智能化企业汉赞迪完成近亿元首轮融资,比邻星创投与高瓴创投共同领投

Mailman

共发表文章3242篇

最近内容
  • 一分钟看懂谷歌、苹果、亚马逊、微软数字健康布局

    2022-01-01

  • 动脉橙产业智库发布《2020全球数字健康产业发展趋势展望》

    2020-08-27

  • Glyscend Therapeutics完成2050万美元A轮融资,用于开发针对T2D代谢性疾病的新型口服聚合物类疗法

    2020-06-17

上一篇

超300亿冠脉介入精准诊疗市场,谁将成为国内首家独角兽?

2021-05-06
下一篇

Lingbo Biotech Announces ¥10M Series Pre-A Financing

2021-05-06